Read by QxMD icon Read

International Journal of Clinical Oncology

Xian Hua Gao, Guan Yu Yu, Yong Gang Hong, Wei Lian, Hanumant Chouhan, Yi Xu, Lian Jie Liu, Chen Guang Bai, Wei Zhang
BACKGROUND: Simultaneous detection of multiple molecular biomarkers is helpful in the prediction of treatment response and prognosis for colorectal cancer (CRC) patients. METHODS: A 22-gene panel consisting of 103 hotspot regions was utilized in the formalin-fixed paraffin-embedded (FFPE) tissue samples of 207 CRC patients, using the next-generation sequencing (NGS)-based multiplex PCR technique. Those 22 genes included AKT1, ALK, BRAF, CTNNB1, DDR2, EGFR, ERBB2, ERBB4, FBXW7, FGFR1, FGFR2, FGFR3, KRAS, MAP2K1, MET, NOTCH1, NRAS, PIK3CA, PTEN, SMAD4, STK11, and TP53...
January 5, 2019: International Journal of Clinical Oncology
Kosuke Yoshida, Hiroaki Kajiyama, Masato Yoshihara, Yoshiki Ikeda, Nobuhisa Yoshikawa, Kimihiro Nishino, Fumi Utsumi, Kaoru Niimi, Shiro Suzuki, Fumitaka Kikkawa
BACKGROUND: In cervical cancer, para-aortic lymph nodes are common sites of metastasis. The purpose of the study was to evaluate the clinical benefits of prophylactic irradiation as postoperative therapy. METHODS: A retrospective cohort study was conducted during 2001-2015 at a single institution. Patients with a high risk of para-aortic lymph nodes recurrence were eligible for this study, and we identified patients who had pelvic lymph node metastasis and underwent radical surgery and concurrent chemo-radiotherapy...
January 5, 2019: International Journal of Clinical Oncology
Masamichi Yasuno, Hiroyuki Uetake, Megumi Ishiguro, Nobuyuki Mizunuma, Takamichi Komori, Go Miyata, Akio Shiomi, Tatsuo Kagimura, Kenichi Sugihara
BACKGROUND: The TRICC0808 trial is a phase II multi-institutional trial that investigated the efficacy of preoperative mFOLFOX6 + bevacizumab (BV) therapy for liver-only metastasis that is unsuitable for upfront resection. The R0 resection rate in the efficacy analysis has been reported to be 44.4%, and the final analysis for survival was conducted (data fixation on February 16, 2015). METHODS: Six cycles of mFOLFOX6 + BV therapy were applied to patients with liver-only metastases, which were > 5 cm in diameter or more than four tumors (H2 and H3), and hepatectomy was performed if possible...
January 5, 2019: International Journal of Clinical Oncology
Satoko Ito, Haruyuki Ito, Noriyuki Sato, Yasuo Hirayama, Toshihiko Kusakabe, Takeshi Terui, Kunihiko Ishitani
BACKGROUND: The purpose of this study was to detect background factors that might be associated with the therapeutic and curative outcome of chemotherapy in elderly cancer patients aged over 75 years. METHODS: A retrospective study was conducted for elderly cancer patients aged over 75 years who had received more than 2 courses of chemotherapy at our hospital. We analyzed the relationships between RECIST outcome and background factors, such as age, sex, clinical TNM stage, pre-treatment history, ECOG performance status, serum albumin, and Charlson comorbidity index using logistic regression analysis...
January 3, 2019: International Journal of Clinical Oncology
Jinsoo Rhu, Chan Woo Cho, Kyo Won Lee, Jae Berm Park, Sung Joo Kim
BACKGROUND: This study was designed to identify the optimal maximum duration for delaying salvage operation when recurrence of retroperitoneal liposarcoma (LPS) is suspected. METHODS: Patients who underwent salvage operation at Samsung Medical Center for recurrent retroperitoneal LPS from January 2000 to December 2015 were reviewed. The time interval between recurrence and operation for recurrence was divided by 1, 2 or 3 months. A Cox proportional-hazards model was used to analyze factors related to disease-free survival along with recurrence-to-operation interval divided by 1, 2 or 3 months...
January 2, 2019: International Journal of Clinical Oncology
Yoshitaka Itami, Makito Miyake, Yoshihiro Tatsumi, Daisuke Gotoh, Shunta Hori, Yousuke Morizawa, Kota Iida, Kenta Ohnishi, Yasushi Nakai, Takeshi Inoue, Satoshi Anai, Nobumichi Tanaka, Keiji Shimada, Shuya Hirao, Kiyohide Fujimoto
OBJECTIVE: The present study evaluated the clinical relevance of an integrative preoperative assessment of inflammation-, nutrition-, and muscle-based markers for patients with upper urinary tract urothelial carcinoma (UTUC) undergoing curative nephroureterectomy (NUx). METHODS: The study enrolled 125 patients and the preoperative variables assessed included age, body mass index, neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), platelet-to-lymphocyte ratio (PLR), serum fibrinogen level (Fib), C-reactive protein (CRP), modified Glasgow prognostic score, serum albumin level (Alb), prognostic nutritional index (PNI), skeletal muscle index (SMI), psoas muscle index (PMI), and peak expiratory flow (PEF)...
January 2, 2019: International Journal of Clinical Oncology
Pawel Chrom, Jakub Zolnierek, Lubomir Bodnar, Rafal Stec, Cezary Szczylik
BACKGROUND: We conducted a study to validate the influence of the systemic immune-inflammation index (SII) on overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC) and to verify whether the implementation of the SII in place of neutrophil and platelet counts within the International Metastatic Renal Cell Carcinoma Consortium (IMDC) model might increase its prognostic accuracy. PATIENTS AND METHODS: We retrospectively analyzed consecutive patients with mRCC, who were treated with first-line tyrosine kinase inhibitors from 2008 to 2016 in two major oncology centres in Poland...
January 2, 2019: International Journal of Clinical Oncology
Keisuke Shigeta, Takeo Kosaka, Hiroshi Hongo, Yoshinori Yanai, Kazuhiro Matsumoto, Shinya Morita, Ryuichi Mizuno, Toshiaki Shinojima, Eiji Kikuchi, Mototsugu Oya
BACKGROUND: Our specific aim was to investigate the prognostic value of effective duration of first androgen deprivation therapy (ADT) and to evaluate the clinical impact on early docetaxel administration with oncological outcomes in castration-resistant prostate cancer (CRPC) patients treated with docetaxel. METHODS: We identified 148 mCRPC patients who were treated with 75 mg/m2 docetaxel. We defined 16 months as the threshold for the effective duration of ADT, and defined 12 months as the cut-off time for starting docetaxel from the onset of CRPC...
January 2, 2019: International Journal of Clinical Oncology
Apostolos Gaitanidis, Michail Spathakis, Christos Tsalikidis, Michail Alevizakos, Alexandra Tsaroucha, Michail Pitiakoudis
BACKGROUND: Patients with colorectal cancer are at increased risk of cardiovascular mortality compared to the general population. The purpose of this study is to identify risk factors of cardiovascular mortality in patients with colorectal cancer. METHODS: A retrospective review of the Surveillance Epidemiology and End Results (SEER) database was performed between 2010 and 2014. Standardized Mortality Ratios (SMRs) for cardiovascular mortality were calculated by comparing the number of expected deaths in the United States according to the National Center for Health Statistics (ICD-10 codes I00-I99) to the number of observed deaths in the database...
January 2, 2019: International Journal of Clinical Oncology
Hiroyuki Kubo, Osamu Imataki, Yukiko Hamasaki Kubo, Makiko Uemura, Norimitsu Kadowaki
BACKGROUND: D-index is a recently established clinical tool for assessing neutropenia severity. This study examined whether the D-index can predict the onset of various infections in patients with febrile neutropenia (FN). METHODS: We retrospectively investigated FN events in consecutive patients aged < 65 years who were treated for newly diagnosed acute myeloid leukemia at our institution. We collected data on all FN events during chemotherapy and evaluated the association of FN severity with infectious events...
January 2, 2019: International Journal of Clinical Oncology
Junko Tsuchida, Jami Rothman, Kerry-Ann McDonald, Masayuki Nagahashi, Kazuaki Takabe, Toshifumi Wakai
Precision medicine can be defined as the customization of medical treatment based on the individual genetic profile, which enables one to identify patients who respond to therapies while sparing side effects for those who do not. Breast cancer patients have been treated based on subtyping, which is considered a prototype of precision medicine. Furthermore, the development of multigene panel testing has resulted in a paradigm shift in the treatment of breast cancer. The knowledge generated from the Human Genome Project, and subsequently The Cancer Genome Atlas, has provided the concept of precision medicine, in which cancer patients can be sub-classified based on actionable driver mutations that can be selectively targeted by molecular targeted drugs and treated by appropriate molecular targeted therapies...
January 2, 2019: International Journal of Clinical Oncology
Tomoyasu Yoshihiro, Hitoshi Kusaba, Akitaka Makiyama, Kazuma Kobayashi, Masato Uenomachi, Mamoru Ito, Yasuhiro Doi, Kenji Mitsugi, Tomomi Aikawa, Kotoe Takayoshi, Taito Esaki, Hozumi Shimokawa, Kenji Tsuchihashi, Hiroshi Ariyama, Koichi Akashi, Eishi Baba
BACKGROUND: Dose modification of chemotherapy for metastatic colorectal cancer (MCRC) is often needed, especially in second-line and later-line treatments due to adverse events of previous treatment and poor patient condition. No study has focused on ramucirumab plus modified dose of FOLFIRI for MCRC, and whether low relative dose intensity (RDI) affects treatment efficacy has not been clarified. METHODS: MCRC patients who received ramucirumab plus FOLFIRI, which consisted of 150 mg/m2 of irinotecan, at six institutions were retrospectively analyzed...
January 2, 2019: International Journal of Clinical Oncology
Fumiaki Isohashi, Tadao Takano, Mamiko Onuki, Takahide Arimoto, Naoki Kawamura, Ryusuke Hara, Yoshiaki Kawano, Yukinobu Ota, Haruo Inokuchi, Hidenori Shinjo, Toshiaki Saito, Satoe Fujiwara, Takashi Sawasaki, Ken Ando, Koji Horie, Hiroyuki Okamoto, Naoya Murakami, Yoko Hasumi, Takahiro Kasamatsu, Takafumi Toita
BACKGROUND: The aim of this study was to evaluate the effects of treatment with both three-dimensional radiotherapy (3DRT) and weekly 40-mg/m2 cisplatin on postoperative uterine cervical cancer patients with high-risk prognostic factors. METHODS: We conducted a retrospective multi-institutional chart review of postoperative uterine cervical cancer patients with high-risk prognostic factors who had been treated with both 3DRT and weekly 40-mg/m2 cisplatin from 2007 to 2012...
December 22, 2018: International Journal of Clinical Oncology
Jin Huang, Jun-Jie Hang, Xiang-Rong Qin, Jian Huang, Xiao-Yong Wang
BACKGROUND: Genetic polymorphisms of Toll-like receptors play important roles in gastric carcinogenesis. The aim of this study was to determine the role of TLR2-196 to -174 ins/del polymorphism in gastric cancer susceptibility and prognosis. METHODS: This study included 520 people from southern China. Samples were genotyped by the allele-specific polymerase chain reaction, among which 10% were randomly selected for sequencing. The serological method was used to determine Helicobacter pylori...
December 15, 2018: International Journal of Clinical Oncology
Shiho Takeuchi, Shujiro Okuda
In Japan, the National Cancer Center and university hospitals have initiated next-generation sequencing-based in vitro diagnostic testing for cancer patients as a method of clinical sequencing. Based on the molecular alterations detected, physicians can provide approved targeted therapy and access to investigational drugs for cancer patients. However, interpretation of the clinical significance of genomic alterations remains the most severe bottleneck of precision medicine in cancer. Although many research institutes in the United States are developing knowledge bases for interpretation of the tumor alterations and clinical decisions, these knowledge bases are unsuited as sources of reference in Japan due to differences in the information on approved drugs and implementation of clinical trials...
December 12, 2018: International Journal of Clinical Oncology
Toshifumi Wakai, Pankaj Prasoon, Yuki Hirose, Yoshifumi Shimada, Hiroshi Ichikawa, Masayuki Nagahashi
Numerous technical and functional advances in next-generation sequencing (NGS) have led to the adoption of this technique in conventional clinical practice. Recently, large-scale genomic research and NGS technological innovation have revealed many more details of somatic and germline mutations in solid tumors. This development is allowing for the classification of tumor type sub-categories based on genetic alterations in solid tumors, and based on this information, new drugs and targeted therapies are being administered to patients...
December 4, 2018: International Journal of Clinical Oncology
Hirofumi Mukai, Chikako Shimizu, Norikazu Masuda, Shoichiro Ohtani, Shinji Ohno, Masato Takahashi, Yutaka Yamamoto, Reiki Nishimura, Nobuaki Sato, Shozo Ohsumi, Hiroji Iwata, Yuko Mori, Satoshi Hashigaki, Yasuaki Muramatsu, Takashi Nagasawa, Yoshiko Umeyama, Dongrui R Lu, Masakazu Toi
BACKGROUND: In PALOMA-2, palbociclib-letrozole significantly improved progression-free survival (PFS) vs placebo-letrozole in women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced breast cancer (ABC) in the first-line setting. We evaluated the efficacy, safety, and pharmacokinetics of palbociclib in Japanese women in PALOMA-2. METHODS: In this phase 3 study, 666 postmenopausal women with ER+/HER2- ABC were randomized 2:1 to palbociclib (125 mg/day [3 weeks on/1 week off]) plus letrozole (2...
December 4, 2018: International Journal of Clinical Oncology
Yasunori Yoshino, Ayumi Taguchi, Maki Takao, Tomoko Kashiyama, Akiko Furusawa, Masaya Uno, Satoshi Okada, Nao Kino, Toshiharu Yasugi
BACKGROUND: Lymphopenia is associated with poor outcomes in patients with various cancers, but little is known about the prognostic impact of lymphopenia in patients with epithelial ovarian cancer (EOC) after induction chemotherapy (IC). This study investigated the prognostic significance of pre- and post-IC lymphopenia in patients with advanced EOC. METHODS: We reviewed medical records of 68 patients with stage III/IV ovarian, fallopian tube, or peritoneal cancer treated with IC at our institution between 2009 and 2017...
November 30, 2018: International Journal of Clinical Oncology
Yoshiko Kawata, Kazunori Nagasaka, Yoko Matsumoto, Katsutoshi Oda, Michihiro Tanikawa, Kenbun Sone, Mayuyo Mori-Uchino, Tetsushi Tsuruga, Takahide Arimoto, Yutaka Osuga, Tomoyuki Fujii
BACKGROUND: The management of refractory ascites in advanced ovarian cancer (AOC) is vital for patients with abdominal distention, respiratory distress, and anorexia due to massive ascites with cancer peritonitis. We analyzed the benefits of concentrated ascites reinfusion therapy (CART) in the management of AOC. METHODS: We reviewed records of AOC patients who underwent CART between January 2011 and March 2017. We retrospectively analyzed patients' backgrounds and physiological changes, including body weight, abdominal girth, urine volume, blood component values, blood pressure, heart rate, and body temperature before and after CART...
November 24, 2018: International Journal of Clinical Oncology
Akihiro Tomida, Keisuke Uehara, Kazuhiro Hiramatsu, Atsuyuki Maeda, Eiji Sakamoto, Yoshito Okada, Yasuhiro Kurumiya, Goro Nakayama, Masanao Nakamura, Toshisada Aiba, Masato Nagino
BACKGROUND: Neoadjuvant chemotherapy (NAC) alone for locally advanced rectal cancer (LARC) remains an experimental treatment, and the efficacy in terms of long-term outcome has not been fully elucidated. The N-SOG 03 trial examined the safety and efficacy of neoadjuvant CAPOX and bevacizumab (Bev) without radiotherapy in patients with poor-risk LARC. METHODS: Thirty-two patients with MRI-defined LARC received neoadjuvant CAPOX and Bev followed by curative resection between 2010 and 2011...
November 23, 2018: International Journal of Clinical Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"